Phase I Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Catequentinib (Primary) ; TQB-2858 (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 09 Dec 2021 Status changed from not yet recruiting to recruiting.
- 11 Oct 2021 New trial record